JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

Search

Design Therapeutics Inc

Open

13.7 -9.15

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.41

Max

17.17

Belangrijke statistieken

By Trading Economics

Inkomsten

1M

-16M

Werknemers

54

EBITDA

-1.2M

-18M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+28.02% upside

Dividenden

By Dow Jones

Volgende Winsten

5 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

217M

800M

Vorige openingsprijs

22.85

Vorige sluitingsprijs

13.7

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Design Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 apr 2026, 23:53 UTC

Winsten

Naver Posts Weaker First-Quarter Earnings

29 apr 2026, 23:41 UTC

Populaire aandelen

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 apr 2026, 23:55 UTC

Winsten

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 apr 2026, 23:54 UTC

Winsten

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 apr 2026, 23:52 UTC

Winsten

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 apr 2026, 23:51 UTC

Winsten

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 apr 2026, 23:51 UTC

Marktinformatie

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 apr 2026, 23:34 UTC

Marktinformatie

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 apr 2026, 23:24 UTC

Winsten

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 apr 2026, 23:24 UTC

Winsten

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 apr 2026, 23:24 UTC

Winsten

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 apr 2026, 23:24 UTC

Winsten

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 apr 2026, 23:22 UTC

Winsten

China Longyuan 1Q Net CNY1.70B, Down 14%

29 apr 2026, 23:22 UTC

Winsten

China Longyuan: Power Generation Down 2.9% as of End-March

29 apr 2026, 23:20 UTC

Winsten

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 apr 2026, 23:20 UTC

Winsten

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 apr 2026, 23:19 UTC

Winsten

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 apr 2026, 23:19 UTC

Winsten

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 apr 2026, 23:19 UTC

Winsten

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 apr 2026, 23:19 UTC

Winsten

China Vanke 1Q Loss Narrows>000002.SZ

29 apr 2026, 23:18 UTC

Winsten

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 apr 2026, 23:17 UTC

Winsten

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 apr 2026, 23:15 UTC

Winsten

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 apr 2026, 23:15 UTC

Winsten

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 apr 2026, 23:13 UTC

Winsten

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 apr 2026, 23:12 UTC

Winsten

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 apr 2026, 23:11 UTC

Winsten

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 apr 2026, 23:11 UTC

Winsten

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 apr 2026, 23:04 UTC

Winsten

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 apr 2026, 23:04 UTC

Winsten

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Peer Vergelijking

Prijswijziging

Design Therapeutics Inc Prognose

Koersdoel

By TipRanks

28.02% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16.4 USD  28.02%

Hoogste 20 USD

Laagste 14 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Design Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technische score

By Trading Central

3.26 / 3.63Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
help-icon Live chat